ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74

Key facts

Sponsor

Quratis Inc.

Principal Investigator

Jinhee Lee, DVM, PhD

Quratis Inc.

Intervention

QTP101(biological)

Enrollment

144 enrolled

Eligibility

55-74 years · All sexes

Timeline

2025 – 2026

Study locations (4)

• Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Gyeonggi-do, South Korea
• Yonsei University Severance Hospital, Seoul, South Korea
• The Catholic University of Korea Seoul ST.MARY'S Hospital, Seoul, South Korea
• Ajou University Hospital, Suwon, South Korea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07164742
  Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure)
  Johns Hopkins University
• RECRUITINGNCT07077213
  18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
  Children's Hospital Medical Center, Cincinnati
• ENROLLING BY INVITATIONNANCT06984887
  Evaluation of New TB Diagnostic Tests (NATs) in Pakistan
  Mercy Corps Pakistan
• RECRUITINGNCT07018076
  Candidate Clinical Correlate of Prognostic Outcome for TB Study
  University of California, San Francisco
• RECRUITINGNANCT07271225
  Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting
  Indonesia University
• RECRUITINGNCT06585358
  DoseTB-individualised Dosing by Model-informed Precision Dosing for Pulmonary Tuberculosis
  Karolinska Institutet
• RECRUITINGPHASE3NCT06497465
  Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
  Johns Hopkins University
• RECRUITINGNCT07178860
  Respiratory Health and Wellbeing Post Pulmonary Tuberculosis
  Liverpool School of Tropical Medicine

See all trials for Tuberculosis →